Inter-α inhibitor proteins: A novel therapeutic strategy for experimental anthrax infection

Shock

Volumn 35, Issue 1, 2011, Pages 42-44

  Opal, Steven M ^a,b   Lim, Yow Pin ^b,c   Cristofaro, Patricia ^b   Artenstein, Andrew W ^a,b   Kessimian, Noubar ^a,b   Delsesto, David ^b   Parejo, Nicolas ^a   Palardy, John E ^a   Siryaporn, Edward ^c  

^a MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^b BROWN UNIVERSITY   (United States)

^c ProThera Biologics   (United States)

Author keywords

Anthrax; inter ! inhibitors; lethal toxin; protease inhibitor; protective antigen; sepsis

Indexed keywords

ANTHRAX TOXIN; ANTIINFECTIVE AGENT; FURIN; INTER ALPHA INHIBITOR PROTEIN; MOXIFLOXACIN; PLACEBO; PLASMA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTHRAX; ANTIMICROBIAL THERAPY; ARTICLE; BACILLUS ANTHRACIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; MALE; MEGAKARYOCYTE ERYTHROID PROGENITOR; MOUSE; NONHUMAN; SEPSIS;

ALPHA-GLOBULINS; ANIMALS; ANTHRAX; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; BACILLUS ANTHRACIS; HUMANS; LIVER; MALE; MICE; QUINOLINES; SPLEEN;

EID: 78650782761     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181e83204     Document Type: Article

References (22)

1. Bost F, Diarra-Mehrpour M, Martin J: Inter-alpha-inhibitor-trypsin inhibitor proteoglycan family; a group of proteins binding and stabilizing the extracellular matrix. Eur J Biochem 252:339-349, 1998.
2. Opal SM, Lim Y-P, Siryaporn E, Pribble JP, Palardy JE, Souza S: Longitudinal studies of inter-alpha inhibitor proteins in severely septic patients: a potential clinical marker and mediator of severe sepsis. Crit Care Med 35(2):387-392, 2007.
3. Lim Y-P, Bendelja K, Opal SM, Siryaporn E, Hixon DC, Palardy JE: Correlation between mortality and the levels of inter-alpha inhibitors in the plasma of patients with severe sepsis. J Infect Dis 188:919-926, 2003.
4. 1- and ulinastatin-based immunomodulatory strategy for sepsis arising from intra-abdominal infection due to carbapenem-resistant bacteria. J Infect Dis 198:723-730, 2008.
5. 1. J Intensive Care Med 24:47-53, 2009.
6. John AT, Collier J: Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Ann Rev Biochem 76:243-265, 2007.
7. Molloy S, Bresnahan P, Leppla S, Klimpel KR, Thomas G: Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Argx-x-arg and efficiently cleaves anthrax toxin protective antigen. J Biol Chem 267: 16396-16402, 2002.
8. Opal SM, Artenstein AW, Cristofaro PA, Jhung JW, Palardy JE. Parejo NA, Lim YP: Inter-alpha-inhibitor proteins are endogenous furin inhibitors and provide protection against experimental anthrax intoxication. Infect Immun 73(8):5101-5105, 2005.
9. Petosa C, Collier RJ, Klimpel KR, Leppla SH, Liddington RC: Crystal structure of the anthrax toxin protective antigen. Nature 385:833-838, 1997.
10. Chen Z, Moayeri M, Zhou Y-H, Leppla S, Emerson S, Sebrell A, Yu F, Svitel J, Schuck P, St. Claire M: Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen. J Infect Dis 193:625-633, 2006.
11. Jean F, Stella K, Thomas L, Liu G, Xiang Y, Reason AJ, Thomas G: Alpha antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent. Proc Natl Acad Sci USA 95:7293-7298, 1998.
12. Garatzoitis S, Hollingsworth JW, Ghanayem RB, Timberlake S, Zhuo L, Kimata K, Schwartz DA: InterY!-trypsin inhibitor attenuates complement activation and complement-induced lung injury. J Immunol 179:4187-4192, 2007.
13. Josic D, Brown MK, Huang F, Lim YP, Rucevic M, Clifton JG, Hixson DC: Proteomic characterization on inter-alpha inhibitor proteins from human plasma. Proteomics 6(9):2874-2885, 2006.
14. Lyons CR, Lovchik J, Hutt J, Lipscomb MF, Wang E, Heninger S, Berliba L, Garrison K: Murine model of pulmonary anthrax: Kinetics of dissemination, histopathology, and mouse strain susceptibility. Infect Immun 72(8):4801-4809, 2004.
15. Piris-Gimenez A, Corre J-P, Jouvion G, Candela T, Khun H, Goossens PL: Encapsulated Bacillus anthracis interacts closely with live endothelium. J Infect Dis 200:1381-1389, 2009.
16. Gregory SH, Sagnimeni AJ, Wing EJ: Bacteria in the bloodstream are trapped in the liver and killed by immigrating neutrophils. J Immunol 157:2514-2520, 1996.
17. Inglesby TV, O'Tolle T, Henderson DA, Bartlett JG, Ascher MS. Eitzen E, Friedlander AM, Gerberding J, Hauer J, Hughes J: Anthrax as a biological weapon: medical and public health management. JAMA 287(17):2236-2252, 2002.
18. Mock M, Fouet A: Anthrax. Annu Rev Microbiol 55:647-671, 2001.
19. Tournier JN, Quesnel-Hellmann A, Cleret A, Vidal DR: Contribution of toxins to the pathogenesis of inhalational anthrax. Cell Microbiol 9:555-565, 2007.
20. Erwin JL, DaSilva LM, Bavari S, Little SF, Friedlander AM, Chanh TC: Macrophase-derived cell lines do not express proinflammatory cytokines after exposure to Bacillus anthracis lethal toxin. Infect Immun 69(2):1175-1177, 2001.
21. Agrawal A, Lingappa J, Leppla SH, Agrawal S, Jabbar A, Quinn C, Pulendran B: Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature 424:329-334, 2003. (Pubitemid 36899376)
22. Pickering AK, Osorio M, Lee GM, Grippe VK, Bray M, Merkel TJ: Cytokine response to infection with Bacillus anthracis spores. Infect Immun 72(11): 6382-6389, 2004.